
Phathom Pharmaceuticals shows negative capital efficiency, destroying value amid high R&D costs.
Phathom Pharmaceuticals currently has a negative Return on Invested Capital (ROIC) of -53.45%, which is much lower than its Weighted Average Cost of Capital (WACC) of 15.49%, indicating it is destroying shareholder value. This is common in clinical-s...

